C-Type Natriuretic Peptide (CNP) (1-22), human

O=C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CC2=CC=CC=C2)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NC1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN

[1]Mazarati AM, et al. ANP (1-28), BNP (1-32) and CNP (1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52 (3) :PL19-24.|[2]Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14 (2) :e0212680.|[3]Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond) . 2000 Nov;99 (5) :467-72.